News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
After a long-standing alliance, Sygnature Group acquired the service provider RenaSci in July 2018.
According to Paul Clewlow, senior VP of business development at Syngature discovery, the acquisition enables the company to provide customers with a “cross-pollination” of service offerings, which Moore will be responsible for promoting.
“Renasci perfectly complements Sygnature’s offerings and our co-location at BioCity Nottingham, UK enables the seamless integration of capabilities within drug discovery and pre-clinical development and affords clients of both companies with the opportunity to augment the technologies and services that can be accessed during drug research and development,” said Clewlow.
RenaSci focuses on the development of therapeutics for the central nervous system (CNS), metabolic disorders, kidney disease, and nonalcoholic steatohepatitis (NASH).
Sygnature Discovery appointed Nick Moore as senior director of business development in an aim to promote RenaSci’s in vivo pharmacology and consulting services.
Moore previously worked at Eli Lilly where he played a key role in the development of the blockbuster drug Zyprexa (olanzapine). He also has worked at Lundbeck Research, and Albany Molecular Research (AMRI) and held business development positions at Brains On-Line and Charles River Laboratories.
Clewlow said that the addition of the role is two-fold, “firstly, it is an interactive role that ensures that customers of both Sygnature Discovery and Renasci are aware of, and can fully benefit from, the wider set of services of the group. Secondly, this is about growth; this position is the frontline of the expansion of our in vivo pharmacology services and the reach into new segments of the pre-clinical drug discovery market.”